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Fluoroquinolones are an important class of anti-bacterials, but as with many anti-infectives,
drug-resistance is an increasing problem. Fluoroquinolones inhibit DNA-gyrase, an enzyme,
which is able to alter the topology of DNA. However, there is only little structural information.
In the literature, there are two rather different proposals for the binding mode of quinolones.
Via docking calculations and MD simulations, we find both binding possibilities and consider
the evidence for each. Work is now underway to test our models with site directed mutagenesis
techniques.
1 Introduction
Despite modern antibiotics, infectious diseases are responsible for nearly one third of hu-
man deaths worldwide, and bacterial resistance is still an urgent problem. The class of
fluoroquinolone(FQ)-antibiotics is a good example. They offer a broad spectrum of activ-
ity, good pharmakokinetic properties and are relatively cheap to produce. However, FQ
resistant bacteria are wide spread.
The functional target and biochemical action of FQs is known. The drugs inhibit the
A2B2 DNA-gyrase tetramer, an enzyme which is able to alter the topology of DNA by
transient cleavage1. This is performed by an esterification of GyrA-Tyr122-OH of the
enyzme to a 5′-phosphate of the DNA. FQs appear to inhibit the religation of the DNA
by stabilizing the cleaved form, ultimately resulting in bacterial cell-death2. Furthermore,
studies of natural and in-vitro mutants offer clues as to which residues are involved in drug-
resistance3. Unfortunately, the exact molecular action remains largely unknown. Clearly,
understanding the drug-enzyme-DNA interaction in molecular terms could be the basis for
the development of new FQ-derivatives refractory to resistance. Due to the lack of com-
plete structural information for the tetramer in complex with DNA and FQ, we have been
trying to build molecular models using a combination of docking methods and molecular
dynamics (MD) simulations.
2 Methods
2.1 Protein-DNA-Docking and Filtering
The mode of gyrase action can roughly be divided into three individual steps. First, the
DNA approaches the protein. Secondly, a phosphate (DNA) - tyrosine (protein) ester is
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formed. Finally, the DNA gap is resealed by a trans-esterification and subsequent DNA re-
lease. How the protein and the DNA find each other can be regarded as a docking problem.
Hence, the first step was to generate many possible DNA-enzyme conformations using
a standard protein-DNA docking tool4. Results are filtered according to orientations of
the DNA 5′-end w.r.t. to the protein’s active site Tyr122, distances between GyrA-Tyr122-
OH and appropriate DNA cleavage sites (5′-↓GRYC-3′)5, as well as electrostatic surface
potentials.
2.2 Molecular Dynamics Simulations and Molecular Docking
Two successive sets of MD simulations were performed to find plausible and stable models
of the protein-DNA complex. In the first set, DNA and protein were not linked while in the
second set, a covalent bond between GyrA-Tyr122-OH and the DNA 5′-end was introduced.
In between, implausible results were discarded. MD simulations, including 70.000 TIP4P
water molecules, were run up to 2ns using GROMACS6.
Subsequently, remaining complexes were used for molecular docking of eleven dif-
ferent quinolones using AutoDock47. For each of the drugs, 250 different conformations
and their binding modes within a box were sampled. The box was defined to contain the
potential binding pocket between Ser83 and Asp87 in the QRDR (quinolone resistance de-
termining region) of GyrA (residues 67-106) as well as the four overhanging bases of the
cleaved dsDNA.
3 Results and Discussion
The first docking session (protein-DNA) yielded >1000 candidates of which 24 were se-
lected for the initial MD simulations (section 2). Of these, two had distances between
GyrA-Tyr122-OH and the DNA 5′-end which allowed the DNA-protein ester to be intro-
duced.
We can distinguish these complexes by the orientation of the nucleic acid w.r.t. the α4
helix of the DNA binding HTH motif present in the QRDR. The first complex places α4
in the major groove of the DNA as proposed by Liddington1, whereas the second complex
supports the model of Lapogonov8 with α4 in the minor groove of DNA. For each drug
molecule in both complexes, a conformational cluster analysis was performed which was
based on positional RMSD of corresponding drug atoms.
For our Lapogonov-like complex, we found a noticeable difference between the clus-
ters containing the highest scoring FQ conformations. Although the drug molecules were
placed within the same binding cavity, they appear to be rotated by ∼180◦ as shown in
fig. 1. Amongst all sampled conformations, these drug arrangements were found most fre-
quently without showing noticeable deviations with respect to their quantities. Our model
indicates that the ligands might be spatially fixed with DNA and enzyme by two main an-
chors. On the one side, the N-containing heterocyclic substituent at C7 could be able to
interact with the phosphate backbone of guanine or cytosine residues of the DNA. How-
ever, in its protonated form, this heterocycle might also interact with backbone oxygens of
Ser83 and Ala84. On the other side, the carboxyl moeity at C3 of the FQs might form a salt-
bridge with the free amino-group of guanine. Moreover, our results could also allow the
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presence of Mg2+ ions9, which might fill the gap (7.5-8.6 A˚) between the FQ’s carboxyl-
and keto-group, respectively, and the phosphate backbone of the DNA.
For the Liddington-like model, the highest scoring FQ conformations did not fit into
the proposed binding cavity. However, as fig. 2 shows, lower scoring dockings are found
for each FQ without clear preferences for a certain conformation. Anyhow, all dockings
are in agreement with the common literature since they satisfy the intercalating nature of
the quinolones.
This theoretical data enabled us to identify amino acids which are currently used to test
the validity of our models with site directed mutagenesis.
Figure 1. Complex of DNA linked to GyrA-Tyr122 and docked quinolones: COOH-moeities of ligands
point out of (left) and into plane (right); enzyme shown in grey, QRDR in lightblue, Ser83, Ala84 and
Asp87 in α4 helix in yellow, orange and magenta, resp.; G in green, C in yellow, T in blue and A in
red.
Figure 2. Liddington-like complex of DNA linked to GyrA-Tyr122 and docked quinolones; color cod-
ing as in fig. 1; pictures were built using UCSF Chimera10.
Acknowledgments
This work is generously supported by the Ju¨rgen Manchot Stiftung, Germany and a grant
of the University of Hamburg, Germany.
291
References
1. J H Cabral, A P Jackson, C V Smith, N Shikotra, A Maxwell, and R C Liddington,
Crystal structure of the breakage-reunion domain of DNA gyrase, Nature, 388, no.
6645, 903–906, 1997.
2. W A Goss, W H Deitz, and T M Cook, Mechanism of action of nalidixic acid on
Eschrichia coli - Inhibition of deoxyribonucleic acid synthesis, J Bacteriol, 89, 1068–
1074, 1965.
3. H Yoshida, M Bogaki, M Nakamura, and S Nakamura, Quinolone resistance-
determining region in the DNA gyrase gyrA gene of Escherichia coli, Antimicrob
Agents Chemother, 34, no. 6, 1271–1272, 1990.
4. D Schneidman-Duhovny, Y Inbar, R Nussinov, and H J Wolfson, PatchDock and
SymmDock: servers for rigid and symmetric docking, Nucleic Acids Res, 33, no.
Web Server issue, W363–7, 2005.
5. C G Noble, F M Barnard, and A Maxwell, Quinolone-DNA interaction: sequence-
dependent binding to single-stranded DNA reflects the interaction within the gyrase-
DNA complex, Antimicrob Agents Chemother, 47, no. 3, 854–862, 2003.
6. D Van Der Spoel, E Lindahl, B Hess, G Groenhof, A E Mark, and H J C Berendsen,
GROMACS: fast, flexible, and free., J Comput Chem, 26, no. 16, 1701–1718, 2005.
7. G M Morris, D S Goodsell, R Huey, W Hart, R Belew, and A J Olson, Automated
Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free En-
ergy Function, J Comput Chem, 19, 1639–1662, 1998.
8. I Laponogov, D A Veselkov, M K Sohi, X Pan, A Achari, C Yang, J Ferrara, L M
Fisher, and M Sanderson, Breakage-Reunion Domain of Streptococcus pneumoniae
Topoisomerase IV: Crystal Structure of a Gram-Positive Quinolone Target, PLoS
ONE, 2, e301, 2007.
9. G Palu, S Valisena, G Ciarrocchi, B Gatto, and M Palumbo, Quinolone binding to
DNA is mediated by magnesium ions., Proc Natl Acad Sci U S A, 89, no. 20, 9671–
9675, 1992.
10. E Pettersen, T Goddard, C Huang, G Couch, D Greenblatt, E Meng, and T Ferrin,
UCSF Chimera–a visualization system for exploratory research and analysis, J Com-
put Chem, 25, no. 13, 1605–1612, 2004.
292
